2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5555 Baseline allele burden predicts disease evolution in polycythemia vera in a long-term real-world cohort

Marie E Piatski, MD, Thalia Padilla Kelley, MD2, Rebecca Pontius, MD3, Eric Bleem, DO4, Aamna Khan, MD5, Jessica Duong, BS6, Kylee L. Martens, MD7, Joseph Shatzel, MD8, Corinne Lavasseur, MD9
1 Oregon Health & Science University, Portland, Oregon, United States
2 Oregon Health & Science University, Portland, Oregon, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
8 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
9 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States

Background: Polycythemia vera (PV) is a JAK2-driven myeloproliferative neoplasm, with the JAK2 V617F mutation present in approximately 95% of patients. JAK2 V617F variant allele frequency (VAF) has been proposed as a quantitative biomarker of disease biology with higher allele burden linked to increased risk of transformation and thrombosis. The clinical utility of the initial allele burden as predictor of long-term disease evolution such as transformation to myelofibrosis (MF) or acute myeloid leukemia (AML) remains an area of interest with the development of disease-modifying therapies. We evaluated whether baseline JAK2 V617F allele burden at diagnosis is associated with subsequent transformation to MF and AML and increased risk of thrombosis over multiple decades in a real-world cohort of patients with PV.  

Methods: We conducted a single-center retrospective study of adult patients ≥ 18 years with confirmed JAK2 V617F PV seen at Oregon Health & Science University between Jan 1982 and Dec 2025. We excluded patients with secondary polycythemia and patients without records available from initial diagnosis. Patients were initially screened based on ICD-10 code, followed by individualized chart review. Pertinent variables collected include demographics, date of diagnosis, risk classification, JAK2 V617F VAF at diagnosis, treatment modalities, and number of lines of therapy. The primary endpoint was defined as transformation to MF or AML by bone marrow biopsy, and secondary endpoints included type and timing of venous or arterial thrombosis. Data was analyzed in SPSS. Associations between baseline JAK2 V617F VAF and clinical outcomes were evaluated using multivariable logistic regression. VAF was analyzed both as a continuous variable (per 10% increase) and as an ordinal categorical variable (0-25%, 26-50%, 51-75%, and 76-100%). Multivariable models for transformation were adjusted for age, sex, high-risk disease status, prior thrombosis, and treatment burden. Models evaluating thrombosis were adjusted for age, sex, and high-risk disease status. 

Results: Of 333 patients included in this analysis, 144 (43.2%) had a confirmed JAK2 V617F variant allele fraction (VAF) measured at diagnosis, with a mean VAF of 51.5%. During follow-up (mean 9.38 years), those with a JAK2 VAF recorded, 28 patients (19.4%) transformed to MF or AML (22 developed MF [15.2%], 7 developed AML [4.9%], with 1 developing both). Higher baseline JAK2 V617F allele burden was independently associated with increased odds of transformation (adjusted odds ratio [aOR] 1.23 per 10% increase, 95% confidence interval [CI] 1.03–1.46; P=0.023) after adjustment for age, sex, high-risk disease status and treatment burden. Consistent with this finding, the risk of transformation increased across baseline JAK2 V617F VAF categories (0–25%, 26–50%, 51–75%, and 76–100%), with each successive category associated with higher odds of transformation (odds ratio [OR] 1.74, 95% CI 1.10–2.75; P=0.019) on Cochran-Armitage Trend. Compared to patients with VAF≤25%, those with baseline VAF 51–75% and 76–100% had greater odds of transformation to MF or AML. In contrast, baseline allele burden was not independently associated with overall thrombosis risk (adjusted OR 0.93, 95% CI 0.79–1.08; p=0.335) or venous thromboembolism (aOR 0.95, 95% CI 0.81–1.12; p=0.557) after adjustment for age, sex, and high-risk PV status. A non-significant trend toward reduced arterial thrombotic risk was observed with increasing allele burden (aOR 0.77 per 10% increase, 95% CI 0.57–1.04; p=0.089).   

Conclusions: Higher baseline JAK2 V617F allele burden was associated with increased odds of fibrotic or leukemic transformation but not thrombotic events in this long-term real-world PV cohort. These findings support further investigation of JAK2 V617F allele burden as a biomarker for longitudinal risk assessment and highlight the importance of evaluating the long-term impact of disease-modifying therapies that reduce molecular burden.

Marie E Piatski, MD: No relevant conflicts of interest to declare.